Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Simply fill out the form, and our dedicated support team will provide you with personalized assistance
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Effects on glucose metabolism and weight are minimal and inconsistent
Institutional and partner-tier accounts can request extended analytical reports including residual solvent profiles, full MS fragmentation data, and lot retention samples
US$ 27.84
US$ 25.89
:max_bytes(150000):strip_icc()/VWH-MiraNorian-WeightLossDrugUpdate-4000x2700-c813fa5051604eec9c136047fb44d23a.png)
US$ 20.31
US$ 23.20
